Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The variability in likelihood ratios due to different mechanisms.
Bright JA, Stevenson KE, Curran JM, Buckleton JS. Bright JA, et al. Among authors: stevenson ke. Forensic Sci Int Genet. 2015 Jan;14:187-90. doi: 10.1016/j.fsigen.2014.10.013. Epub 2014 Oct 25. Forensic Sci Int Genet. 2015. PMID: 25450791
STRmix™ collaborative exercise on DNA mixture interpretation.
Bright JA, Cheng K, Kerr Z, McGovern C, Kelly H, Moretti TR, Smith MA, Bieber FR, Budowle B, Coble MD, Alghafri R, Allen PS, Barber A, Beamer V, Buettner C, Russell M, Gehrig C, Hicks T, Charak J, Cheong-Wing K, Ciecko A, Davis CT, Donley M, Pedersen N, Gartside B, Granger D, Greer-Ritzheimer M, Reisinger E, Kennedy J, Grammer E, Kaplan M, Hansen D, Larsen HJ, Laureano A, Li C, Lien E, Lindberg E, Kelly C, Mallinder B, Malsom S, Yacovone-Margetts A, McWhorter A, Prajapati SM, Powell T, Shutler G, Stevenson K, Stonehouse AR, Smith L, Murakami J, Halsing E, Wright D, Clark L, Taylor DA, Buckleton J. Bright JA, et al. Forensic Sci Int Genet. 2019 May;40:1-8. doi: 10.1016/j.fsigen.2019.01.006. Epub 2019 Jan 15. Forensic Sci Int Genet. 2019. PMID: 30665115
Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease.
Winter PS, Ramseier ML, Navia AW, Saksena S, Strouf H, Senhaji N, DenAdel A, Mirza M, An HH, Bilal L, Dennis P, Leahy CS, Shigemori K, Galves-Reyes J, Zhang Y, Powers F, Mulugeta N, Gupta AJ, Calistri N, Van Scoyk A, Jones K, Liu H, Stevenson KE, Ren S, Luskin MR, Couturier CP, Amini AP, Raghavan S, Kimmerling RJ, Stevens MM, Crawford L, Weinstock DM, Manalis SR, Shalek AK, Murakami MA. Winter PS, et al. Among authors: stevenson ke. bioRxiv [Preprint]. 2024 Jun 10:2024.06.06.597767. doi: 10.1101/2024.06.06.597767. bioRxiv. 2024. PMID: 38915726 Free PMC article. Preprint.
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Lane AA, Garcia JS, Raulston EG, Garzon JL, Galinsky I, Baxter EW, Leonard R, DeAngelo DJ, Luskin MR, Reilly CR, Stahl M, Stone RM, Vedula RS, Wadleigh MM, Winer ES, Mughal T, Brooks C, Gupta IV, Stevenson KE, Neuberg DS, Ren S, Keating J, Konopleva M, Stein A, Pemmaraju N. Lane AA, et al. Among authors: stevenson ke. Blood Adv. 2024 Feb 13;8(3):591-602. doi: 10.1182/bloodadvances.2023011721. Blood Adv. 2024. PMID: 38052038 Free PMC article. Clinical Trial.
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
Wu G, Yoshida N, Liu J, Zhang X, Xiong Y, Heavican-Foral TB, Mandato E, Liu H, Nelson GM, Yang L, Chen R, Donovan KA, Jones MK, Roshal M, Zhang Y, Xu R, Nirmal AJ, Jain S, Leahy C, Jones KL, Stevenson KE, Galasso N, Ganesan N, Chang T, Wu WC, Louissaint A, Debaize L, Yoon H, Dal Cin P, Chan WC, Ho Sui SJ, Ng SY, Feldman AL, Horwitz SM, Adelman K, Fischer ES, Chen CW, Weinstock DM, Brown M. Wu G, et al. Among authors: stevenson ke. Sci Transl Med. 2023 Sep 20;15(714):eadi7244. doi: 10.1126/scitranslmed.adi7244. Epub 2023 Sep 20. Sci Transl Med. 2023. PMID: 37729434 Free PMC article.
Impairment of health-related quality of life for children with acute lymphoblastic leukemia over the first year of therapy: A report from the DFCI ALL Consortium.
Welch JJG, Flamand Y, Stevenson KE, Neuberg DS, Athale UH, Kelly KM, Laverdiere C, Michon B, Place AE, Sallan SE, Silverman LB, Vrooman LM. Welch JJG, et al. Among authors: stevenson ke. Pediatr Blood Cancer. 2023 Nov;70(11):e30560. doi: 10.1002/pbc.30560. Epub 2023 Jul 17. Pediatr Blood Cancer. 2023. PMID: 37461125 Clinical Trial.
New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.
Arwood ML, Liu Y, Harkins SK, Weinstock DM, Yang L, Stevenson KE, Plana OD, Dong J, Cirka H, Jones KL, Virtanen AT, Gupta DG, Ceas A, Lawney B, Yoda A, Leahy C, Hao M, He Z, Choi HG, Wang Y, Silvennoinen O, Hubbard SR, Zhang T, Gray NS, Li LS. Arwood ML, et al. Among authors: stevenson ke. Cell Chem Biol. 2023 Jun 15;30(6):618-631.e12. doi: 10.1016/j.chembiol.2023.05.007. Epub 2023 Jun 7. Cell Chem Biol. 2023. PMID: 37290440 Free PMC article.
100 results